Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.
1 report, 1 independent
Updated May 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
-
National University of Singapore
autonomous research university in Singapore
-
National Research Foundation
government organization in Singapore, Singapore
Nothing else this week.
Related events
- International agency reports cancer statistics in the Philippines, with MSD and Roche supporting an advocacy summit.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.
- Genentech collaboration supports Duality Biotherapeutics' DUPAC platform confidence.